Cure­Vac names a US sub­sidiary CEO to ad­vance mR­NA work; Sune­sis shares slide af­ter reg­u­la­tors nix drug app

→ Ger­many’s Cure­Vac has named a US CEO to help ad­vance its work on mR­NA. And not sur­pris­ing­ly he’ll be based in the Boston/Cam­bridge hub, where ri­val Mod­er­na has been at­tract­ing at­ten­tion — of all va­ri­eties. “As CEO of Cure­Vac Inc., my goal will be to ex­pand Cure­Vac’s US busi­ness en­ti­ty and to fo­cus the cor­po­rate de­vel­op­ment ef­forts to grow our busi­ness glob­al­ly,” said Daniel Menichel­la, who’s tak­ing the post.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.